Reuters news agency reported on Wednesday that according to a source, Serum Institute of India has received Indian regulatory approval, from the Drugs Controller General of India, to resume local clinical trials of British pharmaceutical company AstraZeneca's potential COVID-19 vaccine.
Reportedly, AstraZeneca has resumed British clinical trials of the vaccine, considered one of the most advanced in development for COVID-19, after they were paused earlier this month following a serious side effect in a trial participant.
Trials have also resumed in Brazil and South Africa.
However, the trial remains on hold in the US, as confirmed by the US Food and Drug Administration on 15 September 2020.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval